March 20, 2026

Theravance Biopharma, Inc. (TBPH): Investor Outlook Reveals 13% Potential Upside Amid Strategic Biotech Ventures

Theravance Biopharma, Inc. (NASDAQ: TBPH) is a noteworthy player in the biotechnology sector, capturing investor attention with its compelling growth prospects and strategic collaborations. Based in..

Syndax Pharmaceuticals (SNDX) Investor Outlook: Exploring a 63% Potential Upside in the Biotech Arena

For investors with an eye on the biotechnology sector, Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) presents a compelling opportunity, underscored by a potential upside of 63.26%. With..

Neuropace, Inc. (NPCE) Investor Outlook: Exploring a 51.37% Potential Upside in the Medical Device Sector

Neuropace, Inc. (NASDAQ: NPCE), a promising player in the healthcare sector, particularly in the medical device industry, is capturing the attention of investors with its innovative..

LifeMD, Inc. (LFMD) Stock Analysis: Examining a 141% Potential Upside in the Healthcare Sector

LifeMD, Inc. (NASDAQ: LFMD) stands out in the healthcare sector with its direct-to-patient telehealth services, offering a promising yet complex investment opportunity. Based in New York,..

Claritev Corporation (CTEV) Stock Analysis: Potential 178.68% Upside Captivates Investor Interest

Claritev Corporation (NASDAQ: CTEV), a key player in the health information services industry, is capturing investor attention with a striking potential upside of 178.68%. The company..

Embecta Corp. (EMBC) Stock Analysis: Exploring Potential Upside with a Dividend Yield of 6.59%

Embecta Corp. (NASDAQ: EMBC) is making waves in the healthcare sector, particularly for investors focused on the medical instruments and supplies industry. This U.S.-based company, with..

Capricor Therapeutics, Inc. (CAPR): Investor Outlook on a Promising 72% Upside Potential

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, is capturing the attention of investors with its groundbreaking work in cell and exosome-based therapeutics, particularly for..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Unveiling a 159.68% Potential Upside

AbCellera Biologics Inc. (NASDAQ: ABCL), a prominent player in the biotechnology sector, presents a fascinating opportunity for investors drawn to the healthcare industry. Headquartered in Vancouver,..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a 29.68% Upside Potential

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to targeting fibroblast growth factor receptor..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring the 121.51% Upside Potential

Vir Biotechnology, Inc. (NASDAQ: VIR) is garnering significant attention in the investor community, particularly due to its impressive potential upside of 121.51%. This clinical-stage biopharmaceutical company,..

Talkspace, Inc. (TALK) Stock Analysis: Exploring a 19.88% Potential Upside in the Healthcare Sector

Investors eager to tap into the burgeoning healthcare sector may find Talkspace, Inc. (NASDAQ: TALK) an intriguing prospect. As a virtual behavioral healthcare provider, Talkspace connects..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking a 66% Potential Upside with Strong Buy Ratings

Relay Therapeutics, Inc. (NASDAQ: RLAY), a clinical-stage precision medicines company, is capturing investor attention with its notable potential upside and unanimous buy ratings from analysts. Specializing..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a Promising 58.72% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stands out in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With a market capitalization of $1.55..

Immatics N.V. (IMTX) Investor Outlook: Exploring a 93% Potential Upside in the Biotech Sector

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, is capturing investor attention with its promising position in the dynamic biotechnology industry. Specializing..

Definitive Healthcare Corp. (DH) Stock Analysis: Exploring a Potential 177% Upside

Definitive Healthcare Corp. (NASDAQ: DH) presents a compelling opportunity for investors seeking potential high returns in the healthcare sector. Despite its current challenges, the company’s strategic..

Arvinas, Inc. (ARVN) Stock Analysis: Exploring a 30% Upside Potential in Biotechnology

Arvinas, Inc. (NASDAQ: ARVN) is making waves in the biotechnology sector with its innovative approach to drug development, focusing on the degradation of disease-causing proteins. As..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Evaluating the Upside in a Specialty Drug Innovator

Phibro Animal Health Corporation (NASDAQ: PAHC) stands as a significant player in the healthcare sector, specifically within the drug manufacturing industry focusing on specialty and generic..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Uncovering a 102.98% Potential Upside in Biotech

Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, is attracting significant attention in the biotechnology industry with its promising pipeline and remarkable potential upside. Situated..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Strong Buy Ratings and a 56.51% Upside Potential

Cogent Biosciences, Inc. (NASDAQ: COGT) is garnering significant attention in the biotechnology sector, with a market capitalization of $5.62 billion. As a clinical-stage biotechnology company, Cogent..

Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech with a Potential 282.83% Upside

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company based in San Diego, is making waves in the biotechnology industry with its innovative approach to cancer..

Search

Funds

March 20, 2026

Search

Funds

March 20, 2026

FTSE 100

Funds